



QVAR[®] (beclomethasone dipropionate) – Drug discontinuation

- On August 16, 2017, the FDA announced the discontinuation of Teva's QVAR (beclomethasone dipropionate HFA) inhalation aerosol due to business reasons.
 - QVAR is estimated to be available through March 2018.
- QVAR is indicated in the maintenance treatment of asthma as prophylactic therapy in patients ≥ 5 years of age. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for the systemic corticosteroids.
 - QVAR is not indicated for the relief of acute bronchospasm.
- Teva plans to replace QVAR with QVAR RediHaler[™] (beclomethasone dipropionate HFA) in the first quarter of 2018. QVAR RediHaler contains the same active ingredient as QVAR. QVAR RediHaler uses a breath-actuated metered-dose inhaler, eliminating the need for hand-breath coordination during inhalation.
- QVAR RediHaler is indicated for the maintenance treatment of asthma as prophylactic therapy in patients ≥ 4 years of age; it is not indicated for the relief of acute bronchospasm.
- QVAR and QVAR RediHaler are different products and QVAR RediHaler will require a new prescription from a healthcare provider.
- Teva plans to send notifications regarding the discontinuation of QVAR and transition to QVAR RediHaler to healthcare providers, pharmacists and current patients on February 1, 2018, via letters, digital marketing (eg, emails), and representative visits.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.